InvestorsHub Logo
Post# of 251837
Next 10
Followers 829
Posts 119653
Boards Moderated 16
Alias Born 09/05/2002

Re: dewophile post# 237851

Monday, 11/29/2021 10:11:44 AM

Monday, November 29, 2021 10:11:44 AM

Post# of 251837
BMY—Deucravacitinib for psoriasis has 9/10/22 PDUFA date (with standard FDA review):

https://www.businesswire.com/news/home/20211129005192/en

The Deucra MAA in psoriasis has also been validated by the EMA.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.